Ara
Toplam kayıt 18, listelenen: 1-10
Prognostic Value of Procalcitonin in Infection-Related Mortality of Cancer Patients
(2016)
Purpose: Infectious diseases are a major cause of morbidity and mortality in cancer patients. Tumor-induced inflammatory responses may increase the value of classical inflammatory markers in blood, so these markers may not ...
Investigational Tests and Treatments Performed in Terminal Stage Cancer Patients in Two Weeks Before Death: Turkish Oncology Group (TOG) Study
(2014)
Although more palliative care is necessary for terminally ill cancer patients, excess investigational tests, invasive procedures, and treatments are given instead. Between November 2009 and December 2013, six hundred and ...
Clinicohistopathological features and treatment outcomes of neuroendocrine tumors: a single center experience
(2018)
Purpose: Tumor and patient characteristics of neuroendocrine tumors (NET) significantly change between geographical locations that probably induced by environmental and genetic factors throughout the world. Therefore, ...
Neutrophil-to-lymphocyte Ratio Predicts PSA Response, but not Outcomes in Patients with Castration-Resistant Prostate Cancer Treated with Docetaxel
(2014)
The neutrophil-to-lymphocyte ratio (NLR) is a marker of systemic inflammatory response and evidences for the relationship between NLR and the response to treatment gradually increases in cancer patients. In this study, we ...
The Clinicopathological and Survival Differences Between Never and Ever Smokers with Non-Small Cell Lung Cancer
(2014)
Purpose: Cigarette smoking was regarded as the most important carcinogenic factor of lung cancer, yet in recent years lung cancer in never-smokers is an increasingly prominent public health issue. The aim of this study was ...
GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients
(2020)
Lorlatinib is a third-generation tyrosine-kinases inhibitor (TKI) targeting ALK/ROS1 fusions. The FDA has approved lorlatinib for TKI-pretreated ALK(+) NSCLC, while its approval for ROS1( + ) is still pending. Here we ...
Targeted treatment with pazopanib in metastatic soft tissue sarcoma: Nearly complete response in two cases
(2015)
Soft tissue sarcomas (STS) are a group of rare mesenchymal cancers that include approximately 50 histological types and account for 1% of all adult cancers. The standard curative treatment option for localized disease is ...